

Date: March 27, 2024

RESEARCH ANALYSIS REPORT
ESTIMATION OF AWARENESS AND USE OF *IQOS* AMONG
UNDERAGE INDIVIDUALS 13-20 YEARS OF AGE

Analysis of Relevant Data from the ALCS Underage Tobacco Use Survey
(Short Title: Analysis of UTUS)

Lead Analyst:

Nadja Richter, Ph.D.

Altria Client Services LLC

601 E. Jackson Street

Richmond, Virginia 23219

Phone : (b) (6)

Email : (b) (6)

Sponsor:

Altria Client Services LLC (ALCS)

P.O. Box 26583

Richmond, VA 23261-6583

Sponsor Contact:

Andrea Vansickel, Ph.D.

Altria Client Services LLC

601 E. Jackson Street

Richmond, VA 23219

Phone : (b) (6)

Email : (b) (6)

Date: March 27, 2024

Signature Page

Version: Final 1.0 (27 March 2024)

(b) (6)

3/27/2024

Nadja Richter, Ph.D.
Principal Investigator

Date (day month year)

(b) (6)

3/27/2024

Andrea R. Vansickel
Senior Principal Scientist
Sponsor Contact

Date (day month year)

TABLE OF CONTENTS

1.	INTRODUCTION	4
1.1.	Background.....	4
1.2.	Rationale	4
2.	PURPOSE AND OBJECTIVES.....	5
2.1.	Purpose	5
2.2.	Objectives	5
3.	OVERVIEW OF ALCS' UNDERAGE TOBACCO USE SURVEY (UTUS)	5
3.1.	UTUS Sample Design.....	6
3.2.	UTUS <i>IQOS</i> Module	7
3.3.	UTUS Study Duration	7
3.4.	UTUS Participant Recruitment.....	7
3.5.	UTUS Participant Inclusion Criteria	8
3.6.	Protection of Human Subjects in UTUS.....	8
3.7.	Survey Weighting	9
4.	ANALYSIS APPROACH	10
4.1.	Analysis Objectives and Measures	10
4.2.	Data Analysis.....	12
5.	RESULTS	13
5.1.	Awareness of <i>IQOS</i> among underage individuals (Objective 1).....	13
5.2.	Lifetime and past 30-day <i>IQOS</i> use (Objective 2).....	16
5.3.	Lifetime use behavior among underage ever users of <i>IQOS</i> (Objective 3)	17
5.4.	Past 30-day use behavior among underage past 30-day <i>IQOS</i> users (Objective 4)	17
6.	APPENDIX 1 – SELECTED UTUS QUESTIONS RELATED TO <i>IQOS</i> AND RELEVANT TO CURRENT ANALYSIS REPORT	18

LIST OF TABLES

Table 1:	Estimated awareness of <i>IQOS</i> among 13–20-year-olds	14
Table 2:	Estimated source of awareness of <i>IQOS</i> among 13–20-year-olds who are aware of <i>IQOS</i> (n=255); % (95% CI)	15
Table 3:	Estimated ever [#] and past 30-day ^{##} use of <i>IQOS</i> by demographic characteristics	16

1. INTRODUCTION

1.1. Background

Philip Morris Products S.A. (PMP S.A.) developed the *IQOS* Tobacco Heating System and Marlboro HeatSticks (hereinafter referred to as *IQOS*) as novel tobacco and nicotine-containing products with the potential to reduce harm or the risk of tobacco-related disease associated with smoking cigarettes. PMP S.A. submitted Modified Risk Tobacco Product Applications for *IQOS* to the U.S. Food and Drug Administration (FDA) seeking authorization to market the products as modified risk tobacco products. On July 7, 2020, FDA issued “Modified Risk Granted Orders – Exposure Modification” authorizing *IQOS* to be marketed with a reduced exposure claim. The Orders are conditioned upon agreement to conduct postmarket surveillance and studies (PMSS) in accordance with protocols approved by FDA. This document is prepared as part of the PMSS program for *IQOS* pursuant to the Orders.

1.2. Rationale

The Federal Food, Drug and Cosmetic Act (FDCA) directs the Food and Drug Administration (FDA) to condition an exposure modification order received under FDCA § 911(g)(2) on the MRTP applicants’ agreement to conduct PMSS (FDCA §§ 911(g)(2)(C)(ii)). “The outcomes evaluated in postmarket surveillance and studies should focus on the effect of the MRTP on consumer perception, behavior and health under real world conditions of use” (Food and Drug Administration, 2012). For this reason, ALCS¹ on behalf of the applicant, PMP S.A., plans to conduct certain components of PMSS to assess the effect of the MRTP among U.S. consumers. The program consists of a collection of data over time that supports an assessment of *IQOS* in the postmarket setting.

The current research analysis to estimate awareness and use of *IQOS* among underage individuals 13 to 20 years of age is one component of the PMSS program. Specifically, it uses data relevant to *IQOS* from ALCS’s ongoing Underage Tobacco Use Survey (UTUS) to address FDA’s requirement for *IQOS* PMSS monitoring of youth and young adults below the legal age to purchase tobacco products².

¹ Altria Client Services (ALCS) and the parent of PMP S.A., Philip Morris International Management S.A., have entered into a distribution agreement by which ALCS and its affiliates have exclusive rights to distribute and sell *IQOS* in the U.S. after FDA authorization. ALCS affiliate PM USA markets *IQOS* in the U.S. Therefore, PMSS that involves the study of consumers and consumption in the U.S. will be conducted by ALCS to be submitted as part of PMSS reporting by PMP S.A.

² In the “Modified Risk Granted Orders-Exposure Modification” (July 7, 2020), FDA indicated that “..., given the novelty of these products and the uncertainty related to the impact of modified risk information on youth, your studies must be designed to monitor individuals under the age of 18 to assess: (a) youth awareness of *IQOS*, to evaluate how effectively your marketing is limiting unintended exposure to youth,

Date: March 27, 2024

2. PURPOSE AND OBJECTIVES

2.1. Purpose

The purpose of this analysis is to estimate the awareness and use of *IQOS* among underage individuals based on relevant data from a U.S. nationwide population-based survey.

2.2. Objectives

The objectives of this analysis are to:

- 1) Estimate awareness of *IQOS* among underage individuals
- 2) Estimate ever and past 30-day *IQOS* use among underage individuals
- 3) Estimate lifetime use behavior among underage ever users of *IQOS*
- 4) Estimate past 30-day use behavior among underage past 30-day *IQOS* users

Use behaviors include exclusive, dual and poly tobacco use with *IQOS* and frequency of use. Note that in our reporting approach (described in Section 4) depends on the number of *IQOS* users identified in the UTUS dataset. Outcomes based on subgroups of underage individuals (e.g., estimates based on those aware of *IQOS*, or ever or currently using *IQOS*) will be reported when there are at least 50 respondents in that subgroup.

3. OVERVIEW OF ALCS' UNDERAGE TOBACCO USE SURVEY (UTUS)

We analyzed data from the ALCS Underage Tobacco Use Survey, an on-going national cross-sectional survey of non-institutionalized household dwelling underage individuals (age 13-20) living in the United States (50 states and the District of Columbia). The study assesses the prevalence of tobacco use, patterns of tobacco use, sources of access to tobacco products, and intention to stop using among 13 to 20-year-old tobacco users.

ALCS developed the UTUS to support its underage tobacco prevention and regulatory research and engagement efforts. The UTUS was designed to provide a timely assessment of use behaviors among underage individuals across a range of tobacco product categories. ALCS communicated with FDA on November 15, 2019 its plan to launch the UTUS and shared relevant study materials, including the study protocol, questionnaire, and consent/assent forms.³ The FDA acknowledged the communication and receipt of materials on Dec. 30, 2019. ALCS conducted a pilot study during the first

and (b) youth use of the *IQOS* system, to help ensure that marketing of the MRTPs does not have unintended consequences for youth use. Your surveys must also monitor young adults below the legal age to purchase tobacco products (i.e., ages 18-20).

³ There have been some modifications to the study materials since then.

Date: March 27, 2024

quarter of 2020, launched the full study in May 2020 (Q2 administration), and plans to carry out regular, quarterly survey administrations into the future.

The UTUS is designed to draw nationally representative samples of underage individuals 13-20 years of age using a probability-based sampling method. To better support surveillance of *IQOS* following the MRTP authorization, in quarter 2 of 2021, ALCS added a set of questions designed to specifically assess awareness and use behaviors related to *IQOS* among underage individuals ages 13 to 20. In addition, ALCS started to incorporate oversamples of underage individuals ages 13 to 20 living in US geographies where *IQOS* was available for sale (Atlanta, GA, Charlotte, NC, and Richmond, VA). Following the removal of *IQOS* products from the U.S. markets in late 2021, ALCS stopped oversampling regions in quarter 2 of 2022.⁴

3.1. UTUS Sample Design

The UTUS uses a repeated cross-sectional study design to draw probability samples of non-institutionalized, household-dwelling individuals 13-20 years of age living in the U.S. Study samples are drawn using a list-assisted, address-based-sampling approach utilizing housing unit addresses from the United States Postal Service (USPS) computerized delivery sequence file (CDS) and housing unit addresses flagged as being likely to have a person age 13 to 20 living at the address by the ABS vendor. Group quarters are not included on the sampling frame (e.g., military barracks, group homes, and correctional facilities). To sample housing units, addresses on the sampling frame are stratified by three age groups (13-15, 16-18, 19-20), four Census regions, and urban/rural classification, resulting in a total of 24 strata. Within each stratum, addresses are randomly selected. Within a sampled housing unit, a maximum of two individuals 13-20 years of age are randomly selected. The allowance of two persons per household is used in both US National Survey on Drug Use and Health, as well as the Population Assessment of Tobacco and Health survey.

Initial contact with households is made through a mailed survey invitation letter. Participation is voluntary and participants may choose to complete the survey by online self-administration or phone interview. Due to the unique sensitivities of surveying minors and young adults, the study protocol requires confidentiality, informed assent from all participants, and parent/guardian informed consent for participants 13-17 years of age. A designated Institutional Review Board (IRB) approved the UTUS protocol and oversees the survey.⁵

We launched a pilot execution of the UTUS in the first quarter of 2020 and commenced full execution in the second quarter. The pilot execution successfully demonstrated the

⁴ On January 14, 2022, Philip Morris Products S.A. submitted the *Premarket Tobacco Product Application Amendment and General Correspondence Submission* to LCDR Michael Gu regarding the *Adjustment to the Postmarket Surveillance and Studies (PMSS) Plan for MR0000059 - MR000061 and MR0000133*.

⁵ See this public website for more information on the study design, survey instrument, data sharing policy, as well as updates of recent findings every 6 months: Underage Tobacco Use Survey - Altria Science

Date: March 27, 2024

ability to responsibly collect data, even during the COVID-19 pandemic. We administered quarterly data collections without disruptions through the pandemic.

3.2. UTUS *IQOS* Module

The UTUS *IQOS* module includes questions about awareness, usage, and consumption specific to *IQOS*. See [Section 6](#) for the respective UTUS questions underlying this analysis.

3.3. UTUS Study Duration

UTUS is fielded on a quarterly basis. For the current analysis, data from quarter 2 of 2023 to quarter 1 of 2024 were aggregated to comprise the most recent four-quarter period. The four study waves were conducted between April 4, 2023, and February 13, 2024⁶.

3.4. UTUS Participant Recruitment

Once the sampled housing unit addresses are drawn, a series of four mailings are used to contact each sampled address. In addition, phone calls are made after the last mailing to housing units for which telephone numbers are available via the study vendor. In all cases, an adult household member is required to respond to the survey invitation by providing a housing-unit-specific Access Code, which is included in the mailings. Upon successfully entering the unique Access Code, the responding adult household member enumerates household members to determine if there is at least one member of the household (including students away at college) whose age is between 13 and 20 years. Households containing at least one resident aged 13 to 20 are then administered a household roster to establish a list of eligible study participants in each household. Upon completion of the roster, a maximum of two eligible individuals are randomly selected.

If a selected potential participant is between the ages of 13-17, consent from the participant's parent or legal guardian is required. For all selected individuals, assent is required before taking the survey. Participants can either go to a study website to complete the questionnaire (online self-administration) or call a toll-free telephone number to speak to an interviewer to complete the questionnaire (computer-assisted phone interview). As a summary, the process includes the following steps to determine eligibility, select study participants, obtain informed consent/assent and proceed to the main questionnaire:

⁶ The quarter 2 2022 survey started fielding on April 26, 2022 and the quarter 1 2023 survey closed fielding on February 14, 2023.

Date: March 27, 2024

1. Person completing the screener is asked, “Including yourself, how many people, in each of the following age groups, live in your household at least 50% of the time, or are college students living away from home some of the time?”
2. 12 or younger, 13-20, 21-34, 35-54, or 55 or older
3. Continue with the screener questionnaire if they have person age 13 to 20 in the household.”
4. Household roster is established with age, and sex for each member of household that is age 13-20.
5. Up to 2 members of the household that are age 13-20 are randomly selected.
6. If 1 or 2 minors are selected, collect parental consent.
7. After collecting participant assent, complete the survey.

Both household roster and the main survey can be completed in English or Spanish.

Using this method, a total of 5,676 individuals completed the survey between quarter 2 of 2023 and quarter 1 of 2024.

Participants were able to obtain a token of appreciation upon completion of the questionnaire (in the form of electronic gift cards). For participants aged 13-17 years, their parent/guardian was provided with instructions to obtain the token of appreciation and asked to pass it on to the child.

3.5. UTUS Participant Inclusion Criteria

To qualify for study participation, individuals had to meet the following study eligibility criteria:

- a) Identify as English or Spanish speaking persons living in the United States;
- b) Have access to internet and/or telephone;
- c) 13 to 20 years of age;
- d) Have sufficient abilities to complete the questionnaire (i.e., reading/responding to online survey instrument or listening/speaking to interviewer over the telephone);
- e) 13-17-year-old individuals have received consent from their parent/legal guardian to participate and themselves assent to participate; and
- f) 18-20-year-old individuals consent to participate.

3.6. Protection of Human Subjects in UTUS

A designated Institutional Review Board (IRB) approved the UTUS protocol and oversees the survey. Prior to each quarterly data collection, all relevant documents (e.g., survey protocol, informed parental consent statement, informed participant assent/consent

Date: March 27, 2024

statement, and questionnaire) had been submitted to an Institutional Review Board (IRB) for review and approval.

Participation in UTUS is voluntary. For study participants aged 13 to 17, parental/legal guardian consent is required and recorded through the survey instrument prior to administering the assent form to the minors. All study participants, including minors (age 13 to 17) and adults (age 18 to 20), were administered the informed assent form, and by stating that they would like to participate in the survey after being provided complete information about the study, provided their assent to participate. All participants and parents/guardians of 13–17-year-olds could obtain a copy of the assent or consent statements if they wished.

3.7. Survey Weighting

Survey weights were derived for the combined four quarters data (Q2 2023 to Q1 2024). Survey weighting was carried out at the following stages:

Address Level

- * Base Weights to reflect the selection probability for sampled addresses
- * Exclusion of Non deliverable Addresses to restrict weighting to deliverable addresses present on sampling frame
- * Adjustment for Screener Nonresponse to account for non-participation due to a screener not being completed

Person within Address Level

- * Adjustment for Selection Within Household to reflect the selection probability for sampled persons within an address
- * Adjustment for Parental Non-consent to account for non-participation due to parent/guardian not providing consent for selected minor to participate in survey
- * Adjustment for Selected Person Nonparticipation to account for non-participation due to selected person not assenting to participate in survey or not providing a usable set of responses to the survey
- * Adjustment to Person-Level Population Totals to control weighted counts of completed interviews to total population counts of persons aged 13-20 by characteristics for which estimates are desired and/or which are associated with survey variables of interest (e.g., sex, age category, race/ethnicity, census region, and urban/rural residence)

Weights were trimmed as appropriate, to lessen the impact of extreme weights. Following completion of survey weighting, all records for completed interviews were assigned a final weight which was used to calculate weighted estimates.

4. ANALYSIS APPROACH

Our analysis and annual reporting of *IQOS*-relevant information from UTUS for postmarket surveillance purposes is based on the four most recent study waves conducted, i.e., quarter 2, 2023 through quarter 1, 2024 combined data. A sufficient sample size is needed to ensure adequate precision of estimates (e.g., means and proportions) for the underage population as a whole and among *IQOS* brand users. With a sample size of approximately 5,000 annually, UTUS estimates are generally with reasonable precision. For example, when the point estimate is 1%, the 95% confidence interval (CI) is 0.7% and 1.3% for a sample size of 5,000 respectively. We therefore report awareness of *IQOS* and use of *IQOS* (ever use and past 30-day use) outcomes with their 95% CIs.

For outcomes based on subgroups of underage individuals (e.g., outcomes based on subsets of those aware of *IQOS*, have ever used *IQOS* or used *IQOS* in the past 30 days), we plan to conduct analyses only when there are at least 50 respondents in the respective subgroup as smaller sample sizes can result in unreliable estimates of proportions. With this approach we seek to strike a balance between accurate representation of the data and meaningful interpretation of the results.

4.1. Analysis Objectives and Measures

In this section we provide definitions of outcome measures relevant for the current for *IQOS* PMSS report. Outcome measures are reported for the total study population, and by population subgroups with respect to sex, age, and race/ethnicity when there were at least 50 individuals in a given subgroup (e.g., 13-17-year-olds or 18-20-year-olds).

Objective 1: Estimate awareness and source of awareness of *IQOS* among underage individuals

- Awareness of *IQOS*: percentage of respondents who had seen or heard of *IQOS* before the study, i.e., those who answered “yes” to the question “Have you ever seen or heard of *IQOS* before this study?” (Table 1). Following the survey skip logic, participants who responded “I don’t know” to this question did not receive any further questionnaire items from the *IQOS* module and are not included in this analysis.
- Source of awareness of *IQOS*: among individuals who were aware of *IQOS*, percentage of participants who had indicated how they first became aware of *IQOS* via selecting either one of the respective response options to the question “How did you first see or hear of *IQOS*?” (Table 2).

Objective 2: Estimate ever and past 30-day *IQOS* use among underage individuals

- Prevalence of past 30-day use of *IQOS*: Percentage of respondents who had used *IQOS* within 30 days prior to taking the survey. Past 30-day use of *IQOS* is

Date: March 27, 2024

operationalized as having ever used *IQOS* and used *IQOS* during the past 30 days (i.e., those who selected “*IQOS*” in question “During the past 30 days, what brand or brands of heated tobacco products did you use?” or selected “yes” to the question “During the past 30 days, did you use *IQOS*?”; [Table 3](#)).

- Lifetime ever use⁷ of *IQOS*: Percentage of respondents who had ever used *IQOS* in their lifetime (i.e., those who selected “yes” to the question “Have you ever used *IQOS* before this study, even just one time?”; [Table 3](#)).

Objective 3: Estimate lifetime use behavior among underage ever users of *IQOS*

- Lifetime consumption of heated tobacco: percentages of respondents who had used 1, 2- 10, 11-99, and 100+ of HeatSticks with *IQOS* in their lifetime among ever users of *IQOS*.
- History of other tobacco use among ever *IQOS* users: percentages of respondents who had ever used
 - *IQOS* only
 - *IQOS* and at least one combusted tobacco product
 - *IQOS* and at least one non-combusted tobacco product
 - *IQOS* and both combusted and non-combusted tobacco products

Analysis requires a minimum of 50 ever users of *IQOS* in the sample to compute reliable estimates. Estimates for outcomes listed in objective 3 will be stratified by whether the HeatStick first used was menthol or non-menthol if sample size allows.

Objective 4: Estimate past 30-day use behavior among underage past 30-day *IQOS* users

- Use frequency: median (with interquartile range) and mean (with standard deviation) for the number of days of *IQOS* use during the past 30 days among past 30-day *IQOS* users
- Amount consumed on days used: percentages of respondents who consumed the following number of HeatSticks with *IQOS* on the days they used *IQOS*:
 - ≤ 1 per day
 - 2-5 per day
 - 6-10 per day

⁷ We do not consider lifetime ever use a prevalence measure because it deviates from the traditional definition of prevalence in significant ways and is better described as cumulative incidence among survivors (Streiner et al., 2009).

Date: March 27, 2024

- >10 per day
- Exclusive, dual, and poly tobacco users among past 30-day *IQOS* users: percentages of respondents who used the following in the past 30 days:
 - *IQOS* only
 - *IQOS* and at least one combusted tobacco product
 - *IQOS* and at least one non-combusted tobacco product
 - *IQOS* and both combusted and non-combusted tobacco products

Analysis requires a minimum of 50 past 30-day users of *IQOS* to ensure reliable estimate calculations.

4.2. Data Analysis

We provide summary statistics based on survey-weighted computation, such as point estimates of proportions including 95% CIs. All analyses were conducted using R statistical software version 4.3.1⁸, including the use of the *tidyverse*⁹, *survey*¹⁰, and *srvyr*¹¹ packages. Data were weighted to account for participant selection probabilities, non-response patterns, and adjustments to person-level population totals. Taylor series approximation was used for calculating variances of estimates with *access code* as the primary sampling unit,¹² and the Strata defined as *str* using the following commands in R:

```
#str = (age-1)*100+(ur-1)*10+region  
#svydesign (id = ~ access_code, strata = ~ str, weights = ~ WEIGHT_Q223_Q124,  
data = data)  
#options (survey.lonely.psu = "adjust")
```

Outcome measures are reported for the total study population, and by population subgroups when there were at least 50 individuals in a given subgroup (e.g., 13-17-year-olds or 18-20-year-olds).

Answers of “don’t know” were coded as missing for all above variables. UTUS participants who responded “I don’t know” to the initial question from the respective

⁸ R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.

⁹ Wickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686, <https://doi.org/10.21105/joss.01686>

¹⁰ T. Lumley (2020) "survey: analysis of complex survey samples". R package version 4.0.

¹¹ Greg Freedman Ellis and Ben Schneider (2021). *srvyr*: 'dplyr'-Like Syntax for Summary Statistics of Survey Data. R package version 1.1.0. <https://CRAN.R-project.org/package=srvyr>

¹² The primary sampling units were households, and strata were age (13-15, 16-18, 19-20), urban/rural residence, and geographical regions. The geographical regions consisted of the four Census regions (Northeast, Midwest, South, and West).

Date: March 27, 2024

IQOS module (“Have you ever seen or heard of *IQOS* before this study?”) were not included in the current analysis.

5. RESULTS

A total of 5,676 individuals aged 13 to 20 years participated in the UTUS between April 2023 and February 2024. About 1 in 5 participants responded “I don’t know” to the initial question of the *IQOS* module (*Have you ever seen or heard of IQOS before this study?*). This response prompted a skip of subsequent *IQOS* module questions, resulting in their exclusion from further analysis (n=1,103). An additional 8 participants did not provide an answer to the initial question of the *IQOS* module, which also led to their exclusion from further analysis. The final analysis sample included 4,565 individuals.

5.1. Awareness of *IQOS* among underage individuals (Objective 1)

As shown in [Table 1](#), an overall five percent of underage individuals (n=255) had ever seen or heard of *IQOS* between March 2023 and February 2024.

A weighted 15.7% of the individuals who indicated awareness of *IQOS* (95% CI = 10.3% to 23.2%) also correctly identified the device via the respective survey question¹³ and 46.2% [38.9, 53.7] replied to “not know”. Underage young adults (18-20 years) were more likely to be aware of *IQOS* compared to youth (13-17 years; 9.41% vs. 3.47%; [Table 1](#)).

¹³ Correct identification of *IQOS* was defined as selecting “*This device only uses sticks containing actual tobacco*” to the survey question “*Which of the following best describes IQOS?*”.

Table 1: Estimated awareness of IQOS among 13–20-year-olds

Population Group	Sample size (n)	Awareness [^] % (95% CI)
Overall	4565	5.47 (4.73, 6.32)
Gender		
Female	2365	4.63 (3.75, 5.70)
Male	2200	6.26 (5.16, 7.58)
Age		
13-17 Years	2658	3.47 (2.79, 4.31)
18-20 Years	1907	9.41 (7.87, 11.21)
Race/ethnicity*		
Non-Hispanic White	2571	4.92 (4.08, 5.92)
Non-Hispanic Black	568	5.53 (3.82, 7.93)
Hispanic	1075	5.89 (4.31, 8.01)
Other	286	4.37 (2.39, 7.87)
Non-Hispanic Asian	41	—**
Non-Hispanic Native American/Native Hawaiian	24	—

Source: UTUS data collected from April 2023 to February 2024. Percentages are derived from weighted data. *N*'s are derived from unweighted data. Sample sizes may vary in each subgroup due to missing responses.

[^]The awareness of IQOS was assessed among all participants via the survey question “Have you ever seen or heard of IQOS before this study?” (Response options: yes/no/unsure). The right column in the above presents the weighted proportion of participants who responded ‘Yes’.

*‘Hispanic’ category includes participants who answered “yes” to the first question (*Are you Hispanic, [Latino/Latina], or of Spanish origin?*). ‘Non-Hispanic White’ category includes those who answered “no” to the first question and selected “White” only to the second question (*What is your race? (select all that apply)*). ‘Non-Hispanic Black’ category includes those who answered “no” to the first question and selected “Black” only to the second question. ‘Other’ included those who selected multiple races in the second question.

** Estimates among NH Asian or NH Native American/Hawaiian or other Pacific Islander participants overall were statistically unreliable for all measures and are not presented in this table.

Abbreviations: UTUS = Altria Client Services Underage Tobacco Use Survey; CI = Confidence Interval.

Among those who had ever heard or seen of IQOS (n=255), the most common source of awareness was hearing about it from friends, peers, or classmates (39.24%), followed by seeing advertisements at gas stations, convenience stores, or other retail stores (20.08 %; [Table 2](#)).

Date: March 27, 2024

Table 2: Estimated source of awareness of *IQOS* among 13–20-year-olds who are aware of *IQOS* (n=255); % (95% CI)

Source	Overall (n=255)	13-17 (n=98)	18-20 (n=157)
Saw <i>IQOS</i> in person in a store, mall, convenience store	4.88 (2.48, 9.39)	6.50 (2.66, 15.02)	3.70 (1.26, 10.35)
Saw someone else using <i>IQOS</i>	4.73 (2.69, 8.17)	4.42 (1.72, 10.86)	4.95 (2.44, 9.79)
Saw it on social media (e.g., YouTube or Instagram)	9.18 (6.05, 13.69)	8.86 (4.40, 17.04)	9.41 (5.54, 15.52)
Advertisement at gas stations, convenience stores, or other retail stores	20.08 (14.87, 26.55)	17.22 (10.30, 27.38)	22.16 (15.01, 31.46)
Advertisement in newspapers or magazines	1.19 (0.35, 3.96)	0	2.05 (0.60, 6.76)
Advertisement at festivals, nightclubs, and bars	0.18 (<0.01, 1.27)	0	0.31 (0.04, 2.20)
Advertisement on websites or social media sites	6.80 (3.52, 12.74)	5.33 (1.93, 13.83)	7.87 (3.38, 17.26)
A friend/peer/classmate told me about it	39.24 (32.42, 46.50)	39.21 (29.04, 50.40)	39.26 (30.45, 48.83)
A family member told me about it	5.13 (2.71, 9.51)	7.04 (2.74, 16.90)	3.74 (1.69, 8.10)
Heard or read a story in the news	3.22 (1.28, 7.86)	4.29 (1.20, 14.16)	2.44 (0.53, 10.42)
Other, specify*	1.82 (0.69, 4.73)	2.75 (0.69, 10.29)	1.13 (0.34, 3.69)
Don't know/do not recall	3.57 (1.90, 6.62)	4.39 (1.52, 11.98)	2.98 (1.52, 5.74)

Source: UTUS data collected from April 2023 to February 2024. Based on participant responses to the survey question 'How did you first see or hear of *IQOS*?'. Percentages are derived from weighted data. *N*'s are derived from unweighted data. Sample sizes may vary in each subgroup due to missing responses.

*Five participants used the 'Other' write-in response option to specify where they had first become aware of *IQOS*, of which four indicated through a school/class context.

Abbreviations: UTUS = Altria Client Services Underage Tobacco Use Survey; CI = Confidence Interval.

5.2. Lifetime and past 30-day IQOS use (Objective 2)

A total of 36 individuals in the current dataset reported ever use of IQOS, eight of which reported current (past 30-day) IQOS use.

As shown in Table 3, ever use and past 30-day use of IQOS was low among underage individuals and all subgroups (i.e., about 1% or less).

Table 3: Estimated ever[#] and past 30-day^{##} use of IQOS by demographic characteristics

Population Group	Base Sample (N)	Ever IQOS Use [#] ; % (95% CI)	Ever IQOS Use [#] ; participant count (n)s	Past 30-day IQOS Use ^{##} ; % (95% CI)	Past 30-day IQOS Use ^{##} ; participant count (n)
Overall	4565	0.70 (0.47, 1.06)	36	0.21 (0.08, 0.52)	8
Female	2365	0.38 (0.21, 0.69)	14	0	0
Male	2200	1.00 (0.60, 1.67)	22	0.41 (0.16, 1.01)	8
13-17 Years	2658	0.42 (0.22, 0.80)	10	0.09 (0.02, 0.38)	2
18-20 Years	1907	1.26 (0.80, 1.98)	26	0.44 (0.19, 0.99)	6
Non-Hispanic White	2571	0.57 (0.33, 0.96)	18	0.12 (0.04, 0.39)	3
Non-Hispanic Black	568	0.66 (0.22, 1.96)	4	0.21 (0.03, 1.47)	1
Hispanic	1075	1.07 (0.49, 2.29)	11	0.49 (0.12, 1.92)	4
Other	286	0	0	0	0
Non-Hispanic Asian	41	—**	1	—	0
Non-Hispanic Native American/Native Hawaiian	24	—	2	—	0

Date: March 27, 2024

Source: UTUS data collected from April 2023 to February 2024.

Based on participant responses to the survey question ‘Have you ever used *IQOS* before this study, even just one time?’

Based on participant responses to the survey questions ‘During the past 30 days, did you use *IQOS*? & During the past 30 days, what brand or brands of heated tobacco products did you use?’.

* ‘Hispanic’ included participants who answered “yes” to the first question. ‘Non-Hispanic White’ included those who answered “no” to the first question and selected “White” only to the second question. ‘Non-Hispanic Black’ included those who answered “no” to the first question and selected “Black” only to the second question. ‘Other’ included those who selected multiple races in the second question.

** Estimates among NH Asian or NH Native American/Hawaiian or other Pacific Islander participants overall were statistically unreliable for all measures and are not presented in this table.

Percentages are derived from weighted data. N’s are derived from unweighted data. Sample sizes may vary in each subgroup due to missing responses. Stratified analysis by menthol and non-menthol HeatSticks was not conducted due to low estimates of overall use.

Abbreviations: UTUS = Altria Client Services Underage Tobacco Use Survey; CI = Confidence Interval.

Among the 27 individuals who had indicated use of *IQOS* but not within the past 30 days (i.e., *IQOS* ever-users)¹⁴, three had correctly identified the device while another three had responded to “not know” to the respective survey question.¹⁵

Of the eight individuals who reported use of *IQOS* in the 30 days prior to taking the survey, three correctly identified *IQOS*.

5.3. Lifetime use behavior among underage ever users of *IQOS* (Objective 3)

We did not conduct analyses for objective 3 because the number of ever *IQOS* users in the current dataset (n=36) was not sufficient to compute reliable estimates of use behaviors among the subsample of ever users of *IQOS* (see [Section 4.1](#)).

5.4. Past 30-day use behavior among underage past 30-day *IQOS* users (Objective 4)

We did not conduct analyses for objective 4 because the number of past 30-day *IQOS* users in the current dataset (n=8) was not sufficient to compute reliable estimates of use behaviors among the subsample of past 30-day users of *IQOS* (see [Section 4.1](#)).

¹⁴ A total of 28 individuals in the dataset reported ever use of *IQOS* but one of these individuals did not provide an answer to the question of past-30-day use. Hence, we report a total of 27 individuals who indicated use of *IQOS* but not within the past 30 days.

¹⁵ Note that one out of these 27 individuals did not submit a response to the respective question.

6. APPENDIX 1 – SELECTED UTUS QUESTIONS RELATED TO *IQOS* AND RELEVANT TO CURRENT ANALYSIS REPORT

This appendix provides a list of UTUS survey questions relevant to the current analysis. The UTUS questionnaire is organized in two main parts: assessment of (1) awareness/ever use of various tobacco products, and (2) category-specific modules with questions about tobacco use behaviors in the past 30 days. Tobacco products included in the study are cigarettes, cigars, snuff/dip/chewing tobacco, e-cigarettes, hookah, pipe, snus, heated tobacco, and oral nicotine products.

To support postmarket surveillance requirements, an *IQOS*-specific module was added to the questionnaire in quarter 2 of 2021 and has been included in the UTUS assessment since. The questions from the module, including skip logic, are described here below:

AWARE / EVER USED

3h. And the next question is about heated tobacco products. Some people refer to these products as “heat-not-burn” tobacco products. “Heated tobacco products” heat tobacco sticks or capsules to produce a vapor. They are different from e-cigarettes, which heat a liquid to produce a vapor. Some brands of “heated tobacco products” include *IQOS*, glo™, and Eclipse®.

Have you ever seen or heard of “heated tobacco products” before this study?

Yes - 1

No - 2

(ASK Q.4h IF ‘YES’ AT Q.3h)

4h. Have you **ever used** a “heated tobacco product”, even just one time?

Yes - 1

No - 2

3h1. Have you ever seen or heard of *IQOS* before this study?

Yes - 1

No - 2

Don’t know -99

Date: March 27, 2024

3h8. [Ask if ‘Yes’ at Q.3h1] How did you first see or hear of *IQOS*?

A friend/peer/classmate told me about it	-1
A family member told me about it	-2
Advertisement at gas stations, convenience stores, or other retail stores	-3
Advertisement in newspapers or magazines	-4
Advertisement at festivals, nightclubs, and bars	-5
Advertisement on websites or social media sites	-6
Heard or read a story in the news	-7
Saw <i>IQOS</i> in person in a store, mall, convenience store	-8
Saw someone else using <i>IQOS</i>	-9
Saw it on social media (e.g., YouTube or Instagram)	-10
Other, specify _____	-90
Don’t know/don’t recall	-99

3h9. [Ask if ‘Yes’ at Q.3h1] Which of the following best describes *IQOS*? [Rotate responses 1-4. Keep 1-3 together, rotating within these 3 responses. Always keep “Don’t Know” last.]

This device only uses replaceable pods/cartridges/capsules	-1
This device only uses sticks containing actual tobacco	-2
This device uses both sticks containing actual tobacco <i>and</i> replaceable pods/cartridges/capsules	-3
This device is refilled using bottles of e-liquid	-4
[ALWAYS SHOW LAST] Don’t Know	-99

Date: March 27, 2024

4h1. [Ask if ‘Yes’ at Q.3h1] Have you ever used *IQOS* before this study, even just one time?

Yes	- 1
No	- 2
Don’t know	-99

HEATED TOBACCO PRODUCT SECTION

These next questions are about the use of “heated tobacco products”. Some people refer to these products as “heat-not-burn” tobacco products.

9h. [If Q4h is ‘Yes’] When was the last time you used a heated tobacco product, even one or two times? (*Please select the first answer that fits.*)

Earlier today	-1
Not today but sometime during the past 7 days	-2
Not during the past 7 days but sometime during the past 30 days	-3
Not during the past 30 days but sometime during the past 6 months	-4
Not during the past 6 months but sometime during the past year	-5
1 to 4 years ago	-6
5 or more years ago	-7

Date: March 27, 2024

12h. [If Q9h is 1-3] During the past 30 days, what brand or brands of heated tobacco products did you use? (*select all that apply*)

(Display brand list, only shows *IQOS* if ‘Yes’ at Q.4h1)

Eclipse	-1
Glo	-2
<i>IQOS</i>	-3
PAX	-4
Ploom Tech	-5
Some other brand not listed here	-90 (specify) __
Not sure	-99

***IQOS*-SPECIFIC SECTION**

21hi. You mentioned earlier that you have used *IQOS* before this study. The next questions are about *IQOS*.

[Ask if ‘Yes’ at Q4h1] How many HeatSticks have you used with *IQOS* in your **entire life**?

1	-1
2 to 10	-2
11 to 20	-3
21 to 50	-4
51 to 99	-5
100 or more	-6

Date: March 27, 2024

22hi. [Ask if ‘Yes’ at Q4h1] Menthol HeatSticks are HeatSticks that taste like mint. Was the first *IQOS* HeatStick you used menthol or non-menthol (regular)?

Menthol	- 1
Non-Menthol	- 2
Not sure	-99

23hi. [Ask if ‘Yes’ at Q4h1 AND *IQOS* is not mentioned in Q12h; if *IQOS* is mentioned in Q12h, autofill this question with ‘Yes’ and move to 24hi] During the past 30 days, did you use *IQOS*?

Yes	- 1
No	- 2
Don’t know	-99

24hi. [If ‘Yes’ at Q23hi OR *IQOS* is mentioned in Q12h] During the past 30 days, on how many days did you use *IQOS*?

__ _ Number of days (1-30)

25hi. [If ‘Yes’ at Q23hi OR *IQOS* is mentioned in Q12h] During the past 30 days, on the days you used *IQOS*, about how many HeatSticks did you use with *IQOS* per day?

Less than 1 per day	-1
1 per day	-2
2 to 5 per day	-3
6 to 10 per day	-4
11 to 20 per day	-5
More than 20 per day	-6

Date: March 27, 2024

26hi. [If 'Yes' at Q23hi OR *IQOS* is mentioned in Q12h] During the past 30 days, was the HeatStick you usually used with *IQOS* menthol or non-menthol?

Menthol	-1
Non-Menthol	-2
I did not have a usual type	-97
Not sure	-99

Certificate Of Completion

Envelope Id: (b) (6)		Status: Completed
Subject: Complete with DocuSign: a03-utus-analysis-rep-for-iqos-pmss_FINAL_03272024.docx		
Source Envelope:		
Document Pages: 23	Signatures: 2	Envelope Originator:
Certificate Pages: 5	Initials: 0	Nadja Richter
AutoNav: Enabled		(b) (6)
Envelopeld Stamping: Disabled		IP Address: (b) (6)
Time Zone: (UTC-05:00) Eastern Time (US & Canada)		

Record Tracking

Status: Original	Holder: Nadja Richter	Location: DocuSign
3/27/2024 12:22:59 PM	(b) (6)	

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Andrea Vansickel	(b) (6)	Sent: 3/27/2024 12:25:02 PM
(b) (6)		Viewed: 3/27/2024 1:49:02 PM
Sr. Principal Scientist		Signed: 3/27/2024 1:52:02 PM
(b) (4), (b) (6)		
Security Level: Email, Account Authentication (Required)	Signature Adoption: Pre-selected Style	
	Signature ID:	
	(b) (6)	
	Using IP Address: (b) (6)	
	With Signing Authentication via DocuSign password	
	With Signing Reasons (on each tab):	
	I approve this document	

Electronic Record and Signature Disclosure:
Accepted: 12/20/2022 8:55:53 AM
ID: (b) (6)

Nadja Richter	(b) (6)	Sent: 3/27/2024 12:25:01 PM
(b) (6)		Viewed: 3/27/2024 12:25:35 PM
Senior Scientist II		Signed: 3/27/2024 12:26:07 PM
(b) (4), (b) (6)		
Security Level: Email, Account Authentication (Required)	Signature Adoption: Uploaded Signature Image	
	Signature ID:	
	(b) (6)	
	Using IP Address: (b) (6)	
	With Signing Authentication via DocuSign password	
	With Signing Reasons (on each tab):	
	I am the author of this document	

Electronic Record and Signature Disclosure:
Accepted: 12/19/2022 5:51:02 PM
ID: (b) (6)

In Person Signer Events	Signature	Timestamp
-------------------------	-----------	-----------

Editor Delivery Events	Status	Timestamp
------------------------	--------	-----------

Agent Delivery Events	Status	Timestamp
-----------------------	--------	-----------

Intermediary Delivery Events	Status	Timestamp
------------------------------	--------	-----------

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	3/27/2024 12:25:02 PM
Certified Delivered	Security Checked	3/27/2024 12:25:35 PM
Signing Complete	Security Checked	3/27/2024 12:26:07 PM
Completed	Security Checked	3/27/2024 1:52:02 PM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Altria Client Services CFR Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Altria Client Services CFR Part 11:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: (b) (6)

To advise Altria Client Services CFR Part 11 of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at (b) (6) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Altria Client Services CFR Part 11

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to (b) (6) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Altria Client Services CFR Part 11

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to (b) (6) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Altria Client Services CFR Part 11 as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Altria Client Services CFR Part 11 during the course of your relationship with Altria Client Services CFR Part 11.